1.270USD+2.42%Mkt Cap: 1.45M USDP/E: 0.00Last update: 2026-05-26
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The compa…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.45M USD
Enterprise Value10.56M USD
Revenue (TTM)735.20K USD
Gross Profit632.91K USD
Net Income (TTM)-14.03M USD
Revenue/Share2.201 USD
Last Price1.270 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-1.44
PEG—
EV/EBITDA-1.56
EV/Revenue14.36
P/S1.90
P/B0.29
EPS (TTM)1377.40
EPS (Forward)-0.85
52W Range
0.91000% of range382.50
52W High382.50 USD
52W Low0.9100 USD
Profitability
Gross Margin77.62%
Oper. Margin-9748.80%
EBITDA Margin0.00%
Profit Margin-1720.98%
ROE-89.00%
ROA-56.29%
Growth
Revenue Growth-78.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.68M USD
CapEx (TTM)—
FCF Margin-861.10%
FCF Yield-436.53%
Net Debt-3.43M USD
Net Debt/EBITDA0.51
Balance Sheet
Debt/Equity0.00
Current Ratio1.41
Quick Ratio1.23
Book Value/Sh4.263 USD
Cash/Share0.3240 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMay 21, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.15M
Float10.46M
Insiders—
Institutions—
Short Interest
Short Ratio0.0d
Short % Float4.56%
Short % Out.4.56%
Shares Short52.28K
Short (prev mo.)68.00K
Technical
SMA 5012.05 (-89.5%)
SMA 20087.88 (-98.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.25M
Avg Vol (10d)2.10M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—